Relapsed Refractory Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major relapsed refractory multiple myeloma markets reached a value of US$ 21.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 34.4 Billion by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2024-2034.
The relapsed refractory multiple myeloma market has been comprehensively analyzed in IMARC's new report titled "Relapsed Refractory Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Relapsed refractory multiple myeloma, also known as RRMM, is a type of tumor that affects plasma cells, a form of white blood cell found in the bone marrow. This condition refers to a specific stage of the disease where the cancer has returned after a period of initial therapy and has become resistant to further treatment attempts. It is characterized by the presence of worsening symptoms, such as bone pain, fatigue, anemia, kidney problems, weakness, weight loss, lack of appetite, an increase in abnormal plasma cells in the bone marrow or other parts of the body, etc. An individual suffering from this illness may also experience recurrent infections, numbness in the limbs, difficulty with balance and coordination, changes in mental function, excessive thirst, nausea, confusion, constipation, etc. The diagnosis of RRMM is mainly based on a combination of medical history review, clinical feature assessment, and physical examination. Several imaging techniques, like X-rays, CT scans, MRIs, etc., are also utilized to identify the extent of the disease among patients. The healthcare provider may further perform a bone marrow biopsy to determine the presence and characteristics of cancerous plasma cells.
The increasing cases of genetic abnormalities, including chromosomal rearrangements and mutations in specific genes that can contribute to treatment resistance and disease recurrence, are primarily driving the relapsed refractory multiple myeloma market. In addition to this, the rising prevalence of immune dysregulation, which blocks the function of T cells due to alterations in cytokine levels, is also creating a positive outlook for the market. Moreover, the widespread adoption of proteasome inhibitors, such as bortezomib, carfilzomib, ixazomib, etc., to selectively target and destroy the protein metabolism of abnormal plasma cells is further bolstering the market growth. Apart from this, the inflating application of antibody-drug conjugates that combine a monoclonal antibody with a potent anti-cancer drug to enhance the overall treatment response, thereby potentially leading to better outcomes for patients, is acting as another significant growth-inducing factor. Additionally, the escalating popularity of chimeric antigen receptor T-cell (CAR-T) therapy on account of its various advantages, including targeted treatment, long-term disease control, and improved efficacy, is expected to drive the relapsed refractory multiple myeloma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the relapsed refractory multiple myeloma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for relapsed refractory multiple myeloma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the relapsed refractory multiple myeloma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the relapsed refractory multiple myeloma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the relapsed refractory multiple myeloma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current relapsed refractory multiple myeloma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the relapsed refractory multiple myeloma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the relapsed refractory multiple myeloma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the relapsed refractory multiple myeloma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of relapsed refractory multiple myeloma across the seven major markets?
What is the number of prevalent cases (2018-2034) of relapsed refractory multiple myeloma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of relapsed refractory multiple myeloma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with relapsed refractory multiple myeloma across the seven major markets?
What is the size of the relapsed refractory multiple myeloma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of relapsed refractory multiple myeloma?
What will be the growth rate of patients across the seven major markets?
Relapsed Refractory Multiple Myeloma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for relapsed refractory multiple myeloma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the relapsed refractory multiple myeloma market?
What are the key regulatory events related to the relapsed refractory multiple myeloma market?
What is the structure of clinical trial landscape by status related to the relapsed refractory multiple myeloma market?
What is the structure of clinical trial landscape by phase related to the relapsed refractory multiple myeloma market?
What is the structure of clinical trial landscape by route of administration related to the relapsed refractory multiple myeloma market?
The relapsed refractory multiple myeloma market has been comprehensively analyzed in IMARC's new report titled "Relapsed Refractory Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Relapsed refractory multiple myeloma, also known as RRMM, is a type of tumor that affects plasma cells, a form of white blood cell found in the bone marrow. This condition refers to a specific stage of the disease where the cancer has returned after a period of initial therapy and has become resistant to further treatment attempts. It is characterized by the presence of worsening symptoms, such as bone pain, fatigue, anemia, kidney problems, weakness, weight loss, lack of appetite, an increase in abnormal plasma cells in the bone marrow or other parts of the body, etc. An individual suffering from this illness may also experience recurrent infections, numbness in the limbs, difficulty with balance and coordination, changes in mental function, excessive thirst, nausea, confusion, constipation, etc. The diagnosis of RRMM is mainly based on a combination of medical history review, clinical feature assessment, and physical examination. Several imaging techniques, like X-rays, CT scans, MRIs, etc., are also utilized to identify the extent of the disease among patients. The healthcare provider may further perform a bone marrow biopsy to determine the presence and characteristics of cancerous plasma cells.
The increasing cases of genetic abnormalities, including chromosomal rearrangements and mutations in specific genes that can contribute to treatment resistance and disease recurrence, are primarily driving the relapsed refractory multiple myeloma market. In addition to this, the rising prevalence of immune dysregulation, which blocks the function of T cells due to alterations in cytokine levels, is also creating a positive outlook for the market. Moreover, the widespread adoption of proteasome inhibitors, such as bortezomib, carfilzomib, ixazomib, etc., to selectively target and destroy the protein metabolism of abnormal plasma cells is further bolstering the market growth. Apart from this, the inflating application of antibody-drug conjugates that combine a monoclonal antibody with a potent anti-cancer drug to enhance the overall treatment response, thereby potentially leading to better outcomes for patients, is acting as another significant growth-inducing factor. Additionally, the escalating popularity of chimeric antigen receptor T-cell (CAR-T) therapy on account of its various advantages, including targeted treatment, long-term disease control, and improved efficacy, is expected to drive the relapsed refractory multiple myeloma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the relapsed refractory multiple myeloma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for relapsed refractory multiple myeloma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the relapsed refractory multiple myeloma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the relapsed refractory multiple myeloma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the relapsed refractory multiple myeloma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current relapsed refractory multiple myeloma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the relapsed refractory multiple myeloma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the relapsed refractory multiple myeloma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the relapsed refractory multiple myeloma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of relapsed refractory multiple myeloma across the seven major markets?
What is the number of prevalent cases (2018-2034) of relapsed refractory multiple myeloma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of relapsed refractory multiple myeloma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with relapsed refractory multiple myeloma across the seven major markets?
What is the size of the relapsed refractory multiple myeloma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of relapsed refractory multiple myeloma?
What will be the growth rate of patients across the seven major markets?
Relapsed Refractory Multiple Myeloma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for relapsed refractory multiple myeloma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the relapsed refractory multiple myeloma market?
What are the key regulatory events related to the relapsed refractory multiple myeloma market?
What is the structure of clinical trial landscape by status related to the relapsed refractory multiple myeloma market?
What is the structure of clinical trial landscape by phase related to the relapsed refractory multiple myeloma market?
What is the structure of clinical trial landscape by route of administration related to the relapsed refractory multiple myeloma market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 RELAPSED REFRACTORY MULTIPLE MYELOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 RELAPSED REFRACTORY MULTIPLE MYELOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 RELAPSED REFRACTORY MULTIPLE MYELOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 RELAPSED REFRACTORY MULTIPLE MYELOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 RELAPSED REFRACTORY MULTIPLE MYELOMA - UNMET NEEDS
10 RELAPSED REFRACTORY MULTIPLE MYELOMA - KEY ENDPOINTS OF TREATMENT
11 RELAPSED REFRACTORY MULTIPLE MYELOMA - MARKETED PRODUCTS
11.1 List of Relapsed Refractory Multiple Myeloma Marketed Drugs Across the Top 7 Markets
11.1.1 Carvykti (Ciltacabtagene autoleucel) - Janssen Biotech/Nanjing Legend Biotech
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Abecma (Idecabtagene vicleucel) - 2seventy bio
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Tecvayli (Teclistamab) - Genmab/Janssen Research & Development
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Xpovio (Selinexor) - Karyopharm Therapeutics
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Blenrep (Belantamab mafodotin) - GlaxoSmithKline
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 RELAPSED REFRACTORY MULTIPLE MYELOMA - PIPELINE DRUGS
12.1 List of Relapsed Refractory Multiple Myeloma Pipeline Drugs Across the Top 7 Markets
12.1.1 CART-ddBCMA - Arcellx
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Modakafusp alfa - Takeda/Teva Pharmaceutical Industries
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Venetoclax - AbbVie/Genentech
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 ISB 1442 - Ichnos Sciences
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 ABBV453 - AbbVie
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. RELAPSED REFRACTORY MULTIPLE MYELOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. RELAPSED REFRACTORY MULTIPLE MYELOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 RELAPSED REFRACTORY MULTIPLE MYELOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Relapsed Refractory Multiple Myeloma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Relapsed Refractory Multiple Myeloma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Relapsed Refractory Multiple Myeloma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Relapsed Refractory Multiple Myeloma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Relapsed Refractory Multiple Myeloma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Relapsed Refractory Multiple Myeloma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Relapsed Refractory Multiple Myeloma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Relapsed Refractory Multiple Myeloma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Relapsed Refractory Multiple Myeloma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Relapsed Refractory Multiple Myeloma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Relapsed Refractory Multiple Myeloma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Relapsed Refractory Multiple Myeloma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Relapsed Refractory Multiple Myeloma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Relapsed Refractory Multiple Myeloma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Relapsed Refractory Multiple Myeloma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Relapsed Refractory Multiple Myeloma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Relapsed Refractory Multiple Myeloma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Relapsed Refractory Multiple Myeloma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Relapsed Refractory Multiple Myeloma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Relapsed Refractory Multiple Myeloma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Relapsed Refractory Multiple Myeloma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Relapsed Refractory Multiple Myeloma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Relapsed Refractory Multiple Myeloma - Access and Reimbursement Overview
16 RELAPSED REFRACTORY MULTIPLE MYELOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 RELAPSED REFRACTORY MULTIPLE MYELOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 RELAPSED REFRACTORY MULTIPLE MYELOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 RELAPSED REFRACTORY MULTIPLE MYELOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 RELAPSED REFRACTORY MULTIPLE MYELOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 RELAPSED REFRACTORY MULTIPLE MYELOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 RELAPSED REFRACTORY MULTIPLE MYELOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 RELAPSED REFRACTORY MULTIPLE MYELOMA - UNMET NEEDS
10 RELAPSED REFRACTORY MULTIPLE MYELOMA - KEY ENDPOINTS OF TREATMENT
11 RELAPSED REFRACTORY MULTIPLE MYELOMA - MARKETED PRODUCTS
11.1 List of Relapsed Refractory Multiple Myeloma Marketed Drugs Across the Top 7 Markets
11.1.1 Carvykti (Ciltacabtagene autoleucel) - Janssen Biotech/Nanjing Legend Biotech
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Abecma (Idecabtagene vicleucel) - 2seventy bio
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Tecvayli (Teclistamab) - Genmab/Janssen Research & Development
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Xpovio (Selinexor) - Karyopharm Therapeutics
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Blenrep (Belantamab mafodotin) - GlaxoSmithKline
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 RELAPSED REFRACTORY MULTIPLE MYELOMA - PIPELINE DRUGS
12.1 List of Relapsed Refractory Multiple Myeloma Pipeline Drugs Across the Top 7 Markets
12.1.1 CART-ddBCMA - Arcellx
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Modakafusp alfa - Takeda/Teva Pharmaceutical Industries
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Venetoclax - AbbVie/Genentech
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 ISB 1442 - Ichnos Sciences
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 ABBV453 - AbbVie
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. RELAPSED REFRACTORY MULTIPLE MYELOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. RELAPSED REFRACTORY MULTIPLE MYELOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 RELAPSED REFRACTORY MULTIPLE MYELOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Relapsed Refractory Multiple Myeloma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Relapsed Refractory Multiple Myeloma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Relapsed Refractory Multiple Myeloma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Relapsed Refractory Multiple Myeloma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Relapsed Refractory Multiple Myeloma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Relapsed Refractory Multiple Myeloma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Relapsed Refractory Multiple Myeloma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Relapsed Refractory Multiple Myeloma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Relapsed Refractory Multiple Myeloma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Relapsed Refractory Multiple Myeloma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Relapsed Refractory Multiple Myeloma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Relapsed Refractory Multiple Myeloma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Relapsed Refractory Multiple Myeloma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Relapsed Refractory Multiple Myeloma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Relapsed Refractory Multiple Myeloma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Relapsed Refractory Multiple Myeloma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Relapsed Refractory Multiple Myeloma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Relapsed Refractory Multiple Myeloma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Relapsed Refractory Multiple Myeloma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Relapsed Refractory Multiple Myeloma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Relapsed Refractory Multiple Myeloma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Relapsed Refractory Multiple Myeloma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Relapsed Refractory Multiple Myeloma - Access and Reimbursement Overview
16 RELAPSED REFRACTORY MULTIPLE MYELOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 RELAPSED REFRACTORY MULTIPLE MYELOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 RELAPSED REFRACTORY MULTIPLE MYELOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
